ArticleMedicine2026
Investigation of factors influencing intravenous glucocorticoid treatment course in severe acute urticaria: A retrospective study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute urticaria, a prevalent skin condition characterized by wheals and itching, often requires intravenous glucocorticoids for patients with severe symptoms and systemic manifestations. However, clinical studies investigating factors influencing the intravenous glucocorticoid treatment course in patients with severe acute urticaria are lacking. This retrospective study examines factors influencing intravenous corticosteroid treatment in severe acute urticaria and compares the characteristics of patients with and without infection. This study enrolled 96 patients with severe acute urticaria. Baseline data - sex, age, region, season, accompanying symptoms, triggers, glucocorticoid types, initial dose, neutrophil, platelet, lymphocyte, white blood cell counts, Urticaria Activity Score, and treatment duration were meticulously recorded for each participant. Spearman correlation, Mann-Whitney U and Kruskal-Wallis H tests explored relationships between the treatment course of intravenous glucocorticoids and continuous or categorical variables. Statistically significant variables identified in the univariate analysis were tested using multiple linear regression analysis. Chi-square tests or Spearman correlation were used to compare differences between the infection-triggered and non-infection-triggered groups. Multiple linear regression analysis revealed infection (β = 0.05, [95% confidence interval: 0.02-2.09], P < .05) and elevated neutrophils (β = 1.47, [95% confidence interval: 0.09-2.85], P < .05) to be significantly associated with a prolonged duration of intravenous glucocorticoid therapy in severe acute urticaria patients. No significant differences were observed between infectious and noninfectious acute urticaria groups in the subgroup analysis. Infection and elevated neutrophil count were associated with prolonged intravenous glucocorticoid courses. Investigating other laboratory indicators associated with infection-triggered severe acute urticaria, rather than the neutrophil, lymphocyte, and white blood cell levels, is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.